Still hard to compare Remicade, Enbrel

The presentation of Centocor Inc.'s 54-week data for its Remicade infliximab to treat advanced rheumatoid arthritis provides the first chance to compare long-term data for the anti-tumor necrosis factor antibody against Immunex Corp.'s Enbrel etanercept soluble TNF receptor.

Based on available one-year data, a greater percentage of patients receiving Enbrel had reductions in the number of tender and swollen joint counts